P. Williams

Roles and Competencies for Distance Education Programs in Higher Education Institutions

Peter E Williams, P. Williams, 2003 .

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Design, Formulation, and Evaluation of Novel Dissolving Microarray Patches Containing Rilpivirine for Intravaginal Delivery

H. McCarthy, Eneko Larrañeta, R. Donnelly, 2019, Advanced healthcare materials.

Design, formulation and evaluation of novel dissolving microarray patches containing a long-acting rilpivirine nanosuspension

Ryan F. Donnelly, Eneko Larrañeta, Helen O. McCarthy, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial

D. Podzamczer, B. Clotet, H. Stellbrink, 2017, The Lancet.

Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.

J. Eron, Kimberly Smith, W. Spreen, 2015, The Lancet. Infectious diseases.

Formulation and pharmacology of long-acting rilpivirine

H. Crauwels, E. Basstanie, P. Williams, 2015, Current opinion in HIV and AIDS.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Kaleab Z. Abebe, S. Khoo, C. Dezzutti, 2016, The lancet. HIV.

Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection.

S. Oka, S. Walmsley, C. Orkin, 2020, The New England journal of medicine.

A Multiple Dose Phase 1 Assessment of Rilpivirine Long-Acting in a Model of Pre-Exposure Prophylaxis against HIV.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2019, AIDS research and human retroviruses.

Long-acting rilpivirine as potential pre-exposure prophylaxis for HIV-1 prevention (the MWRI-01 study): an open-label, phase 1, compartmental, pharmacokinetic and pharmacodynamic assessment.

Ross D. Cranston, Kaleab Z. Abebe, S. Khoo, 2016, The lancet. HIV.